1. Home
  2. ATNM

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

Logo Actinium Pharmaceuticals Inc. (Delaware)

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Founded: 2000 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 264.6M IPO Year: N/A
Target Price: $25.72 AVG Volume (30 days): 351.0K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.83 EPS Growth: N/A
52 Week Low/High: $4.00 - $9.86 Next Earning Date: 05-13-2024
Revenue: $81,000 Revenue Growth: -92.14%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Latest Actinium Pharmaceuticals Inc. (Delaware) News

ATNM Breaking Stock News: Dive into ATNM Ticker-Specific Updates for Smart Investing

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

PR Newswire

16 days ago

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

PR Newswire

22 days ago

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

PR Newswire

a month ago

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

PR Newswire

2 months ago

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

InvestorPlace

2 months ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

PR Newswire

2 months ago

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

PR Newswire

3 months ago

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

Business Wire

3 months ago

Templeton Emerging Markets Income Fund ("TEI" or the "Fund") Announces Notification of Sources of Distributions

All ATNM News